Emerald Investment Advisers LLC acquired a new stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,314 shares of the medical instruments supplier's stock, valued at approximately $3,711,000. Emerald Investment Advisers LLC owned about 0.10% of ICU Medical as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP acquired a new position in shares of ICU Medical in the 2nd quarter valued at $26,000. Hilton Head Capital Partners LLC acquired a new stake in shares of ICU Medical during the fourth quarter worth $32,000. Covestor Ltd grew its stake in shares of ICU Medical by 22.1% during the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 126 shares during the period. Strs Ohio increased its holdings in ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier's stock valued at $114,000 after purchasing an additional 300 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its holdings in ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 146 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have issued reports on ICUI shares. Weiss Ratings upgraded ICU Medical from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, July 23rd. Zacks Research cut ICU Medical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Jefferies Financial Group upgraded shares of ICU Medical to a "strong-buy" rating in a report on Thursday, May 7th. Sanford C. Bernstein downgraded shares of ICU Medical to a "market perform" rating in a research note on Monday, June 15th. Finally, Wall Street Zen raised shares of ICU Medical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $192.80.
Check Out Our Latest Analysis on ICU Medical
ICU Medical Price Performance
ICUI stock opened at $182.84 on Friday. The stock has a 50-day moving average price of $160.85 and a two-hundred day moving average price of $143.13. ICU Medical, Inc. has a 1 year low of $112.50 and a 1 year high of $192.85. The stock has a market cap of $4.57 billion, a PE ratio of 154.95, a price-to-earnings-growth ratio of 2.31 and a beta of 0.74. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56.
ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The company had revenue of $547.88 million during the quarter, compared to analysts' expectations of $533.44 million. During the same period in the prior year, the firm earned $2.10 earnings per share. ICU Medical's revenue for the quarter was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities analysts forecast that ICU Medical, Inc. will post 7.19 EPS for the current fiscal year.
Insider Buying and Selling at ICU Medical
In other news, insider Ben Sousa sold 2,250 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total transaction of $401,220.00. Following the sale, the insider owned 3,076 shares in the company, valued at $548,512.32. This represents a 42.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Elisha W. Finney sold 378 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total transaction of $68,977.44. Following the transaction, the director owned 4,871 shares in the company, valued at $888,860.08. This represents a 7.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 16,974 shares of company stock valued at $3,085,844. Corporate insiders own 2.10% of the company's stock.
About ICU Medical
(
Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
